Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of sinoporphyrin sodium photodynamic therapy versus investigator's choice therapy in recurrent or metastatic esophageal cancer
CTR20221271Phase 3Active
- Sponsor
- Qinglong High-Tech
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cosiporfin sodium in esophageal cancer, esophagogastric junction cancer, sponsored by Qinglong High-Tech. Started Aug 2022; status: active.
02
Drugs
cosiporfin sodium
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on CTR20221271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221271.